Dynamic Monitoring of Circulating Tumor DNA to Predict the Risk of Non In Situ Recurrence of Postoperative Glioma: A Prospective Cohort Study
ABSTRACT Background Glioma recurrence can be divided into in situ recurrence and non‐in situ recurrence, and the mutation evolution of gliomas with different recurrence patterns is still unknown. We used sequential sequencing of circulating tumor DNA (ctDNA) to compare the somatic mutation profile a...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-03-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.70733 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850225413901516800 |
|---|---|
| author | Guangzhong Guo Ziyue Zhang Jiubing Zhang Dayang Wang Sensen Xu Shuang Wu Kaiyuan Deng Yage Bu Zhiyuan Sheng Jinliang Yu Yushuai Gao Zhaoyue Yan Ruijiao Zhao Meiyun Wang Tianxiao Li Xingyao Bu |
| author_facet | Guangzhong Guo Ziyue Zhang Jiubing Zhang Dayang Wang Sensen Xu Shuang Wu Kaiyuan Deng Yage Bu Zhiyuan Sheng Jinliang Yu Yushuai Gao Zhaoyue Yan Ruijiao Zhao Meiyun Wang Tianxiao Li Xingyao Bu |
| author_sort | Guangzhong Guo |
| collection | DOAJ |
| description | ABSTRACT Background Glioma recurrence can be divided into in situ recurrence and non‐in situ recurrence, and the mutation evolution of gliomas with different recurrence patterns is still unknown. We used sequential sequencing of circulating tumor DNA (ctDNA) to compare the somatic mutation profile and clonal evolution of gliomas with different recurrence patterns. To investigate the value of ctDNA in predicting early postoperative tumor recurrence and guiding prognosis stratification in patients with glioma. Methods We prospectively recruited 92 patients with near‐total resection of gliomas from our center. Two hundred and thirty‐four postoperative tissue and Tumor In Situ Fluid (TISF) samples from 69 eligible patients were included in ctDNA analysis. Results Among the 69 patients, 37 glioblastoma (GBM) patients experienced recurrence, and the median progression‐free survival (mPFS) was not significantly different between the situ recurrence group and the non‐in situ recurrence group (8.6 vs. 6.1 months). The ctDNA of recurrent tissue and TISF were significantly consistent. Before and after initial treatment, TISF‐ctDNA mutant allele fraction (MAF), subclonal mutation, and alterations in related pathways (lysine degradation and PI3K pathway) were negatively correlated with treatment response and PFS. Among recurrent GBM patients, EGFR mutations were the most common. Mutations related to the RTK‐RAS pathway (NF1) were most common in patients with situ recurrent GBM, while mutations in the MUC family and TP53 pathway (MUC16, CHEK2) were prevalent and continuously increased in patients with non‐in situ recurrent GBM. Conclusions In glioma patients undergoing primary surgery, dynamic monitoring of ctDNA and genotyping can be used for early risk stratification, efficacy monitoring, and early recurrence detection, and provide a basis for clinical research to evaluate early therapeutic intervention. |
| format | Article |
| id | doaj-art-349d84b0733a43eebb5bac1c4f3adbde |
| institution | OA Journals |
| issn | 2045-7634 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj-art-349d84b0733a43eebb5bac1c4f3adbde2025-08-20T02:05:21ZengWileyCancer Medicine2045-76342025-03-01145n/an/a10.1002/cam4.70733Dynamic Monitoring of Circulating Tumor DNA to Predict the Risk of Non In Situ Recurrence of Postoperative Glioma: A Prospective Cohort StudyGuangzhong Guo0Ziyue Zhang1Jiubing Zhang2Dayang Wang3Sensen Xu4Shuang Wu5Kaiyuan Deng6Yage Bu7Zhiyuan Sheng8Jinliang Yu9Yushuai Gao10Zhaoyue Yan11Ruijiao Zhao12Meiyun Wang13Tianxiao Li14Xingyao Bu15Department of Neurosurgery, Juha International Center for Neurosurgery Zhengzhou University People's Hospital Zhengzhou Henan ChinaDepartment of Neurosurgery, Juha International Center for Neurosurgery Zhengzhou University People's Hospital Zhengzhou Henan ChinaDepartment of Neurosurgery, Juha International Center for Neurosurgery Zhengzhou University People's Hospital Zhengzhou Henan ChinaDepartment of Neurosurgery, Juha International Center for Neurosurgery Zhengzhou University People's Hospital Zhengzhou Henan ChinaDepartment of Neurosurgery, Juha International Center for Neurosurgery Zhengzhou University People's Hospital Zhengzhou Henan ChinaDepartment of Neurosurgery, Juha International Center for Neurosurgery Zhengzhou University People's Hospital Zhengzhou Henan ChinaDepartment of Neurosurgery, Juha International Center for Neurosurgery Zhengzhou University People's Hospital Zhengzhou Henan ChinaDepartment of Neurosurgery, Juha International Center for Neurosurgery Zhengzhou University People's Hospital Zhengzhou Henan ChinaDepartment of Neurosurgery, Juha International Center for Neurosurgery Zhengzhou University People's Hospital Zhengzhou Henan ChinaDepartment of Neurosurgery, Juha International Center for Neurosurgery Zhengzhou University People's Hospital Zhengzhou Henan ChinaDepartment of Neurosurgery, Juha International Center for Neurosurgery Zhengzhou University People's Hospital Zhengzhou Henan ChinaDepartment of Neurosurgery, Juha International Center for Neurosurgery Zhengzhou University People's Hospital Zhengzhou Henan ChinaDepartment of Pathology Zhengzhou University People's Hospital, Henan Provincial People's Hospital, Henan University People's Hospital Zhengzhou Henan ChinaDepartment of Radiology Zhengzhou University People's Hospital, Henan Provincial People's Hospital, Henan University People's Hospital Zhengzhou Henan ChinaHenan Provincial Neurointerventional Engineering Research Center, Henan International Joint Laboratory of Cerebrovascular Disease, Henan Engineering Research Center of Cerebrovascular Intervention Innovation Zhengzhou Henan ChinaDepartment of Neurosurgery, Juha International Center for Neurosurgery Zhengzhou University People's Hospital Zhengzhou Henan ChinaABSTRACT Background Glioma recurrence can be divided into in situ recurrence and non‐in situ recurrence, and the mutation evolution of gliomas with different recurrence patterns is still unknown. We used sequential sequencing of circulating tumor DNA (ctDNA) to compare the somatic mutation profile and clonal evolution of gliomas with different recurrence patterns. To investigate the value of ctDNA in predicting early postoperative tumor recurrence and guiding prognosis stratification in patients with glioma. Methods We prospectively recruited 92 patients with near‐total resection of gliomas from our center. Two hundred and thirty‐four postoperative tissue and Tumor In Situ Fluid (TISF) samples from 69 eligible patients were included in ctDNA analysis. Results Among the 69 patients, 37 glioblastoma (GBM) patients experienced recurrence, and the median progression‐free survival (mPFS) was not significantly different between the situ recurrence group and the non‐in situ recurrence group (8.6 vs. 6.1 months). The ctDNA of recurrent tissue and TISF were significantly consistent. Before and after initial treatment, TISF‐ctDNA mutant allele fraction (MAF), subclonal mutation, and alterations in related pathways (lysine degradation and PI3K pathway) were negatively correlated with treatment response and PFS. Among recurrent GBM patients, EGFR mutations were the most common. Mutations related to the RTK‐RAS pathway (NF1) were most common in patients with situ recurrent GBM, while mutations in the MUC family and TP53 pathway (MUC16, CHEK2) were prevalent and continuously increased in patients with non‐in situ recurrent GBM. Conclusions In glioma patients undergoing primary surgery, dynamic monitoring of ctDNA and genotyping can be used for early risk stratification, efficacy monitoring, and early recurrence detection, and provide a basis for clinical research to evaluate early therapeutic intervention.https://doi.org/10.1002/cam4.70733biomarkercirculating tumor DNAclonal evolutiongliomarisk stratificationtumor recurrence |
| spellingShingle | Guangzhong Guo Ziyue Zhang Jiubing Zhang Dayang Wang Sensen Xu Shuang Wu Kaiyuan Deng Yage Bu Zhiyuan Sheng Jinliang Yu Yushuai Gao Zhaoyue Yan Ruijiao Zhao Meiyun Wang Tianxiao Li Xingyao Bu Dynamic Monitoring of Circulating Tumor DNA to Predict the Risk of Non In Situ Recurrence of Postoperative Glioma: A Prospective Cohort Study Cancer Medicine biomarker circulating tumor DNA clonal evolution glioma risk stratification tumor recurrence |
| title | Dynamic Monitoring of Circulating Tumor DNA to Predict the Risk of Non In Situ Recurrence of Postoperative Glioma: A Prospective Cohort Study |
| title_full | Dynamic Monitoring of Circulating Tumor DNA to Predict the Risk of Non In Situ Recurrence of Postoperative Glioma: A Prospective Cohort Study |
| title_fullStr | Dynamic Monitoring of Circulating Tumor DNA to Predict the Risk of Non In Situ Recurrence of Postoperative Glioma: A Prospective Cohort Study |
| title_full_unstemmed | Dynamic Monitoring of Circulating Tumor DNA to Predict the Risk of Non In Situ Recurrence of Postoperative Glioma: A Prospective Cohort Study |
| title_short | Dynamic Monitoring of Circulating Tumor DNA to Predict the Risk of Non In Situ Recurrence of Postoperative Glioma: A Prospective Cohort Study |
| title_sort | dynamic monitoring of circulating tumor dna to predict the risk of non in situ recurrence of postoperative glioma a prospective cohort study |
| topic | biomarker circulating tumor DNA clonal evolution glioma risk stratification tumor recurrence |
| url | https://doi.org/10.1002/cam4.70733 |
| work_keys_str_mv | AT guangzhongguo dynamicmonitoringofcirculatingtumordnatopredicttheriskofnoninsiturecurrenceofpostoperativegliomaaprospectivecohortstudy AT ziyuezhang dynamicmonitoringofcirculatingtumordnatopredicttheriskofnoninsiturecurrenceofpostoperativegliomaaprospectivecohortstudy AT jiubingzhang dynamicmonitoringofcirculatingtumordnatopredicttheriskofnoninsiturecurrenceofpostoperativegliomaaprospectivecohortstudy AT dayangwang dynamicmonitoringofcirculatingtumordnatopredicttheriskofnoninsiturecurrenceofpostoperativegliomaaprospectivecohortstudy AT sensenxu dynamicmonitoringofcirculatingtumordnatopredicttheriskofnoninsiturecurrenceofpostoperativegliomaaprospectivecohortstudy AT shuangwu dynamicmonitoringofcirculatingtumordnatopredicttheriskofnoninsiturecurrenceofpostoperativegliomaaprospectivecohortstudy AT kaiyuandeng dynamicmonitoringofcirculatingtumordnatopredicttheriskofnoninsiturecurrenceofpostoperativegliomaaprospectivecohortstudy AT yagebu dynamicmonitoringofcirculatingtumordnatopredicttheriskofnoninsiturecurrenceofpostoperativegliomaaprospectivecohortstudy AT zhiyuansheng dynamicmonitoringofcirculatingtumordnatopredicttheriskofnoninsiturecurrenceofpostoperativegliomaaprospectivecohortstudy AT jinliangyu dynamicmonitoringofcirculatingtumordnatopredicttheriskofnoninsiturecurrenceofpostoperativegliomaaprospectivecohortstudy AT yushuaigao dynamicmonitoringofcirculatingtumordnatopredicttheriskofnoninsiturecurrenceofpostoperativegliomaaprospectivecohortstudy AT zhaoyueyan dynamicmonitoringofcirculatingtumordnatopredicttheriskofnoninsiturecurrenceofpostoperativegliomaaprospectivecohortstudy AT ruijiaozhao dynamicmonitoringofcirculatingtumordnatopredicttheriskofnoninsiturecurrenceofpostoperativegliomaaprospectivecohortstudy AT meiyunwang dynamicmonitoringofcirculatingtumordnatopredicttheriskofnoninsiturecurrenceofpostoperativegliomaaprospectivecohortstudy AT tianxiaoli dynamicmonitoringofcirculatingtumordnatopredicttheriskofnoninsiturecurrenceofpostoperativegliomaaprospectivecohortstudy AT xingyaobu dynamicmonitoringofcirculatingtumordnatopredicttheriskofnoninsiturecurrenceofpostoperativegliomaaprospectivecohortstudy |